Anixa Biosciences (NASDAQ:ANIX) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Anixa Biosciences (NASDAQ:ANIX) announced its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03, FiscalAI reports.

Anixa Biosciences Trading Down 2.1%

Shares of ANIX stock traded down $0.05 during trading on Wednesday, reaching $2.35. 111,064 shares of the company’s stock traded hands, compared to its average volume of 139,720. The company has a market capitalization of $78.80 million, a P/E ratio of -7.12 and a beta of 0.59. The firm’s 50-day moving average is $2.79 and its 200 day moving average is $3.13. Anixa Biosciences has a 1 year low of $2.35 and a 1 year high of $5.46.

Institutional Trading of Anixa Biosciences

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Anixa Biosciences by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock valued at $4,694,000 after buying an additional 29,436 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Anixa Biosciences by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock valued at $1,095,000 after buying an additional 7,271 shares in the last quarter. Bank of America Corp DE raised its position in shares of Anixa Biosciences by 1.7% during the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after buying an additional 3,645 shares in the last quarter. State Street Corp raised its position in shares of Anixa Biosciences by 32.0% during the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock valued at $496,000 after buying an additional 38,540 shares in the last quarter. Finally, 683 Capital Management LLC purchased a new stake in shares of Anixa Biosciences during the 4th quarter valued at $355,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ANIX has been the topic of several research reports. Wall Street Zen lowered shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Anixa Biosciences has a consensus rating of “Hold” and a consensus price target of $8.50.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.